I have written a series of blog articles on various aspects of structural biology and its contribution to small-molecule and therapeutic antibody drug discovery. See the recent titles:
Antibody structure and engineering: therapeutic monoclonal antibodiesThe development of new drugs of biological origin, the majority of which are monoclonal antibodies, is a major focus of modern-day drug design. The information on monoclonal antibody three-dimensional structure, in combination with antibody engineering, plays a central role in this process and has opened the way for the rapidly growing field of monoclöonal antibody therapeutics.
https://www.saromics.com/blog/biosimilars-structure-comparabilityThe second part of our article series on antibody therapeutics discusses the field of biosimilar therapeutics and the need for higher order structure (HOS) comparability analysis.
Links to earlier posts can be found here.